We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

98 hedge funds and large institutions have $67.8M invested in Aclaris Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $62.4M → $67.8M (+$5.39M)

7.17% less ownership

Funds ownership: 83.94% → 76.77% (-7.2%)

8% less funds holding

Funds holding: 107 → 98 (-9)

19% less call options, than puts

Call options by funds: $76K | Put options by funds: $94K

31% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 39

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
98
Holders Change
-9
Holders Change %
-8.41%
% of All Funds
1.41%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
18
Increased
27
Reduced
39
Closed
27
Calls
$76K
Puts
$94K
Net Calls
-$18K
Net Calls Change
-$43K

Top Buyers

1
BCM
BML Capital Management
Indiana
+$10.4M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.6M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$730K
4
PAI
Palo Alto Investors
California
+$680K
5
AI
Acuitas Investments
Washington
+$551K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.32M
2
VCIM
Velan Capital Investment Management
Georgia
-$1.85M
3
TCM
Tang Capital Management
California
-$1.84M
4
Morgan Stanley
Morgan Stanley
New York
-$1.74M
5
GCP
GSA Capital Partners
United Kingdom
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Blackstone Inc
76
Blackstone Inc
New York
$16.2K – – –
Neuberger Berman Group
77
Neuberger Berman Group
New York
$15.5K -$6.8K -5,704 -31%
Citigroup
78
Citigroup
New York
$15.3K -$590K -495,173 -98%
JFG
79
Jefferies Financial Group
New York
$14.3K – – –
Legal & General Group
80
Legal & General Group
United Kingdom
$12K -$48K -40,249 -81%
Federated Hermes
81
Federated Hermes
Pennsylvania
$10.2K +$4.38K +3,676 +80%
New York State Common Retirement Fund
82
New York State Common Retirement Fund
New York
$9.55K +$655 +549 +8%
California State Teachers Retirement System (CalSTRS)
83
California State Teachers Retirement System (CalSTRS)
California
$8.66K -$57.9K -48,577 -87%
AIP
84
Ameritas Investment Partners
Nebraska
$8.56K – – –
TRCT
85
Tower Research Capital (TRC)
New York
$6.53K -$5.34K -4,477 -46%
Royal Bank of Canada
86
Royal Bank of Canada
Ontario, Canada
$4K -$24.4K -20,423 -87%
AB
87
Amalgamated Bank
New York
$3K -$8.93K -7,491 -76%
HF
88
Halpern Financial
Virginia
$1.88K – – –
CPG
89
Cornerstone Planning Group
New Jersey
$789 +$692 +580 New
Northwestern Mutual Wealth Management
90
Northwestern Mutual Wealth Management
Wisconsin
$620 – – –
TC
91
Truvestments Capital
Florida
$186 – – –
Osaic Holdings
92
Osaic Holdings
Arizona
$154 +$148 +124 New
FFA
93
Farther Finance Advisors
California
$125 +$41 +34 +52%
AWM
94
Avior Wealth Management
Nebraska
$17 +$17 +14 New
FIA
95
FNY Investment Advisers
New York
$12 +$11.9K +10,000 New
VCIM
96
Velan Capital Investment Management
Georgia
– -$1.85M -1,761,595 Closed
TCM
97
Tang Capital Management
California
– -$1.84M -1,753,335 Closed
MAM
98
Monaco Asset Management
Monaco
– -$1.03M -979,399 Closed
Jacobs Levy Equity Management
99
Jacobs Levy Equity Management
New Jersey
– -$786K -748,775 Closed
CC
100
Checkpoint Capital
California
– -$476K -453,614 Closed
1 2 3
4
5

ACRS Hedge Fund Activity: Q1 2024 in Review

98 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2024, worth a combined $67.8M — up 8.6% from $62.4M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of ACRS and 18 opened new positions — a net loss of 9 holders — while 39 trimmed existing stakes and 27 added.

The largest buyer was BML Capital Management, adding an estimated $10.4M. The largest seller was Citadel Advisors, cutting an estimated $5.32M.

  • 98 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2024, down from 107 in Q4 2023.
  • Funds reported $67.8M of Aclaris Therapeutics stock for Q1 2024, up 8.6% quarter-over-quarter.
  • 18 funds opened new Aclaris Therapeutics positions in Q1 2024 and 27 closed out, a net change of -9 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2024 was BML Capital Management, an estimated $10.4M added.
  • The largest Aclaris Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $5.32M sold.

Based on aggregated 13F filings for Q1 2024.